SOURCE: NuLife Sciences, Inc.

NuLife Sciences, Inc.

June 05, 2017 08:00 ET

NuLife Moves Into NSU's Center for Collaborative Research; New, State of the Art Facility Supports NuLife Technique R&D

SAN CLEMENTE, CA--(Marketwired - June 05, 2017) - NuLife Sciences (OTCQB: NULF) through the company's wholly-owned subsidiary, NuLife BioMed, Inc., today announced that it has moved into space at Nova Southeastern University's (NSU) prestigious Center for Collaborative Research (CCR), where it will conduct research on the NuLife Technique, a means to potentially eliminate the need for tissue matching between donor and recipient in kidney transplants and the need for anti-rejection medication post-surgery.

As one of the CCR's first tenants, NuLife has leased 350 square feet of space in the new, state-of-the-art facility, which offers collaboration with NSU's expert researchers and access to the CCR's sophisticated equipment, technology, laboratories. There, it will advance its research and development of its NuLife Technique ranging from basic research to pre-clinical studies that are slated to begin in June 2017.

The CCR is located at the southwest end of Nova Southeastern University's Fort Lauderdale/Davie campus near the NSU Health Professions Division. Researchers and tenants throughout NSU's CCR have access to the following core facilities, further enhancing collaboration opportunities:

  • Genomics Core for sequencing human genes associated with disease
  • Flow Cytometry Core for isolating special cell types such as immune and stem cells
  • Cell Therapy Core for developing immunotherapies and regenerative medicines
  • Imaging Core with advanced digital microscopy capabilities

"The NSU Center for Collaborative Research is exceptional, ideally suited for the specialized research we will be conducting to advance the commercialization of our NuLife Technique," said John Hollister, NuLife Sciences Chief Executive Officer. "It provides NuLife a complete, turnkey solution in a premier academic setting where we will also have access to ancillary resources ranging from undergrad and graduate interns to grant writing expertise and much more.

About Nova Southeastern University's (NSU) Center for Collaborative Research

Nova Southeastern University's (NSU) Center for Collaborative Research (CCR) is one of the largest and most advanced research facilities in Florida.

Located adjacent to the university's Health Professions Division complex on NSU's Fort Lauderdale/Davie Campus, the 215,000-sq. ft., six-story CCR is equipped with wet and dry labs; state-of-the-art research equipment, including access to a high-performance computing environment; and other resources, such as Florida LambdaRail, a high-speed broadband service delivery network with connectivity throughout the nation.

The CCR building has been submitted to the United States Green Building Council for review with the intent of receiving Leadership in Energy and Environmental Design (LEED) gold certification. The CCR took two years to complete and reflects an investment of nearly $100 million in Broward County.

NSU is classified as a research university with "high research activity" by the Carnegie Foundation for the Advancement of Teaching. More than 200 research projects are currently underway at NSU, including studies on cardiovascular disease, anti-cancer therapies, chronic fatigue syndrome, autism, coral reef restoration, stem cells, disorders that cause blindness, wildlife DNA forensics, and more.

About Nova Southeastern University (NSU)

Located in beautiful Fort Lauderdale, Florida, Nova Southeastern University (NSU) is a dynamic research institution dedicated to providing high-quality educational programs at the undergraduate, graduate, and first-professional degree levels. A private, not-for-profit institution, NSU has campuses in Fort Lauderdale, Fort Myers, Jacksonville, Miami, Miramar, Orlando, Palm Beach, and Tampa, Florida, as well as San Juan, Puerto Rico, while maintaining a presence online globally. For more than 50 years, NSU has been awarding degrees in a wide range of fields, while fostering groundbreaking research and an impactful commitment to community. Classified as a research university with "high research activity" by the Carnegie Foundation for the Advancement of Teaching, NSU is 1 of only 50 universities nationwide to also be awarded Carnegie's Community Engagement Classification, and is also the largest private, not-for-profit institution in the United States that meets the U.S. Department of Education's criteria as a Hispanic-serving Institution. Please visit for more information about NSU and for more information on the largest fundraising campaign in NSU history.

About NuLife Sciences

NuLife Sciences Inc. (OTCQB: NULF) is a biomedical company focused on medical research and technology that has the potential to address significant unmet medical needs in applications including transplantation/regenerative medicine/cell therapy/organ and tissue transplants. Through its wholly-owned subsidiary NuLife BioMed, it is currently working on advancing human organ transplant technology based upon a patent protected and unique proprietary method ("NuLife Technique") that could potentially eliminate the need for an organ or tissue match and the necessity for anti-rejection drugs. With a massive need and market for organ transplants, and over 123K candidates waiting for an organ in the U.S. alone, NuLife's versatile technique is suitable for a variety of clinical indications. The Company has completed discovery phase for its technique, and is now entering a Preclinical phase involving animal studies on its pathway to commercialization. For more information please visit

Safe Harbor

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, many of which are beyond the Company's control. The Company's actual results could differ materially and adversely from those anticipated in such forward-looking statements as a result of certain factors, including those set forth below and elsewhere in this press release. All statements, other than statements of historical facts, included in this press release regarding the Company's growth strategy, future operations, financial position, estimated revenue or losses, projected costs, prospects and plans and objectives of management are forward-looking statements. When used in this press release, the words "will," "may," "believe," "anticipate," "intend," "estimate," "expect," "project," "plan" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. All forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update any forward-looking statements or other information contained herein. Potential investors should not place undue reliance on these forward-looking statements. Although the Company believes that its plans, intentions and expectations reflected in or suggested by the forward-looking statements in this press release are reasonable, the Company cannot assure potential investors that these plans, intentions or expectations will be achieved. The Company discloses important factors that could cause the Company's actual results to differ materially from its expectations under "Risk Factors" and elsewhere in this press release. These cautionary statements qualify all forward-looking statements attributable to the Company or persons acting on its behalf.

Contact Information